Influenza A virus
Influenza A virus (IAV) is an enveloped, negative-sense RNA virus in the family Orthomyxoviridae and is a major cause of seasonal influenza in humans and many animal species.
Influenza A virus (IAV) is an enveloped, negative-sense RNA virus in the family Orthomyxoviridae and is a major cause of seasonal influenza in humans and many animal species. It is biologically important because of its high mutation rate, antigenic variation, and capacity for reassortment, all of which contribute to recurrent epidemics, antiviral resistance, and occasional pandemics. The virus primarily infects the respiratory epithelium, which serves as the first immunological barrier and a key site of early host defense.
IAV is medically significant because it can cause illness ranging from uncomplicated upper respiratory infection to severe viral pneumonia, acute lung injury, and death, particularly in young children, older adults, pregnant individuals, and immunocompromised patients. Host responses involving pathways such as MAVS signaling, STAT1-associated inflammation, Toll-like receptor 7/8 signaling, and the toll like receptor 4 (TLR4)/P2X7-NLRP3 axis have been studied in relation to disease severity and antiviral defense. Influenza A virus is also a major target for vaccination and antiviral drug development because of its broad public health burden and its ability to evade immunity through antigenic drift and subtype diversity.
Where the papers sit
12 papers from the last 6 months study Influenza A virus directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 5 observational · 2 human data · 4 preclinical · 1 unclassified
Themes 3 themes
-
Influenza Antiviral Development
Influenza antiviral development is combining vaccine design, small-molecule screening, and delivery engineering rather than relying on a single target. Candidates include H1N1 receptor-binding-domain aggregates, 2-aminoquinoline and coumarin derivatives aimed at viral proteins or RNA-dependent RNA polymerase, and Amaryllidaceae alkaloids with broad-spectrum activity. Ionizable lipid architecture is being optimized for safer, more effective mRNA delivery, while molecular surveillance defines circulating strains. Cytotoxicity, neutralizing responses, and antiviral activity recur as the main filters, but these approaches have not converged on one clinical strategy.
6 papers · 50%
-
Respiratory Infection Prevention
Vaccination and clinical severity are linked across influenza, COVID-19, pertussis, and pneumococcal disease, especially in children and families. Cystic fibrosis care exposes gaps in vaccine coverage, while maternal–infant concordance highlights missed opportunities for protection. Booster vaccination is examined alongside influenza mortality, but hypertransaminasemia is used chiefly as a severity marker rather than a treatment target. The shared agenda is better prevention and risk stratification, with no single intervention trend yet.
4 papers · 33.3%
-
CRISPR-Cas12a Diagnostics
CRISPR-Cas12a diagnostics are moving toward rapid, visual, multiplex, one-pot detection of influenza A, influenza B, and respiratory syncytial virus. Recombinase polymerase amplification supplies nucleic-acid amplification while Cas12a cleavage provides the readout. crRNA scaffold mutation is used to harmonize amplification and cleavage kinetics, addressing robustness in integrated reactions. The open question is whether these optimized assays retain sensitivity and reliability outside controlled testing.
2 papers · 16.7%
Papers
The 12 papers from the last 6 months that study Influenza A virus directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Influenza Antiviral Development (6)
- Design, synthesis, and anti-influenza A virus evaluation of 2-aminoquinoline derivatives. European journal of medicinal chemistry · 4 Aug 2026 PMID 42551133
- Integrated in silico and in vitro approaches reveal novel coumarin hybrids targeting influenza A virus RNA-dependent RNA polymerase. European journal of medicinal chemistry · 22 Jul 2026 PMID 42485991
- Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus. Vaccine · 11 Jul 2026 PMID 42435621
- Discovery of broad-spectrum antiviral activity in Amaryllidaceae alkaloids. Biochemical and biophysical research communications · 8 Jul 2026 PMID 42419220
- Exploring molecular characterization circulating influenza A and B viruses in Tehran, Iran. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 1 Jul 2026 PMID 42384313
- Spatial Tail Design in Ionizable Lipids Enhances the Safety and Efficacy of mRNA Delivery. Small methods · 26 Jun 2026 PMID 42359610
Respiratory Infection Prevention (4)
- Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies. Human vaccines & immunotherapeutics · 29 Jun 2026 PMID 42373575
- Hypertransaminasemia Is a Marker of Severity in Children Hospitalized for Influenza. Influenza and other respiratory viruses · 24 Jun 2026 PMID 42340130
- Concordance Between Maternal and Infant COVID-19 and Influenza Vaccination Status. Pediatrics · 23 Jun 2026 PMID 42336370
- Association between COVID-19 booster vaccination and influenza mortality: a nationwide retrospective cohort study using the SIVEP-Gripe database in Brazil. Immunologic research · 21 Jun 2026 PMID 42324378
CRISPR-Cas12a Diagnostics (2)
- Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics. Proceedings of the National Academy of Sciences of the United States of America · 9 Sept 2026 PMID 42715083
- A rapid, multiplex, one-pot CRISPR/Dx system for visual detection of influenza A, influenza B, and respiratory syncytial viruses. Analytical methods : advancing methods and applications · 16 Jun 2026 PMID 42299927
By study type
Observational studies and case reports (5)
- Exploring molecular characterization circulating influenza A and B viruses in Tehran, Iran. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 1 Jul 2026 PMID 42384313
- Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies. Human vaccines & immunotherapeutics · 29 Jun 2026 PMID 42373575
- Hypertransaminasemia Is a Marker of Severity in Children Hospitalized for Influenza. Influenza and other respiratory viruses · 24 Jun 2026 PMID 42340130
- Concordance Between Maternal and Infant COVID-19 and Influenza Vaccination Status. Pediatrics · 23 Jun 2026 PMID 42336370
- Association between COVID-19 booster vaccination and influenza mortality: a nationwide retrospective cohort study using the SIVEP-Gripe database in Brazil. Immunologic research · 21 Jun 2026 PMID 42324378
Human data, design not indexed (2)
- Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics. Proceedings of the National Academy of Sciences of the United States of America · 9 Sept 2026 PMID 42715083
- A rapid, multiplex, one-pot CRISPR/Dx system for visual detection of influenza A, influenza B, and respiratory syncytial viruses. Analytical methods : advancing methods and applications · 16 Jun 2026 PMID 42299927
Preclinical: animal, cell and lab studies (4)
- Design, synthesis, and anti-influenza A virus evaluation of 2-aminoquinoline derivatives. European journal of medicinal chemistry · 4 Aug 2026 PMID 42551133
- Integrated in silico and in vitro approaches reveal novel coumarin hybrids targeting influenza A virus RNA-dependent RNA polymerase. European journal of medicinal chemistry · 22 Jul 2026 PMID 42485991
- Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus. Vaccine · 11 Jul 2026 PMID 42435621
- Discovery of broad-spectrum antiviral activity in Amaryllidaceae alkaloids. Biochemical and biophysical research communications · 8 Jul 2026 PMID 42419220
Unclassified: not yet indexed with MeSH (1)
- Spatial Tail Design in Ionizable Lipids Enhances the Safety and Efficacy of mRNA Delivery. Small methods · 26 Jun 2026 PMID 42359610
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-06-21. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.